Decibel Therapeutics is a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, one of the largest areas of unmet need in medicine. Decibel has built a proprietary platform that integrates single-cell genomics and bioinformatic analyses, precision gene therapy technologies and expertise in inner ear biology. Decibel is leveraging its platform to advance gene therapies designed to selectively replace genes for the treatment of congenital, monogenic hearing loss and to regenerate inner ear hair cells for the treatment of acquired hearing and balance disorders. Decibel’s pipeline, including its lead gene therapy program, DB-OTO, to treat congenital, monogenic hearing loss, is designed to deliver on our vision of a world in which the privileges of hearing and balance are available to all.
Location: United States, Massachusetts, Boston
Employees: 51-200
Total raised: $189.2M
Founded date: 2015
Investors 5
| Date | Name | Website |
| - | The Longev... | longevity.... |
| - | OrbiMed | orbimed.co... |
| - | Koa Labs | koalab.com |
| - | GV | gv.com |
| - | SR One | srone.com |
Funding Rounds 3
| Date | Series | Amount | Investors |
| 11.11.2020 | Series D | $82.2M | - |
| 19.06.2018 | Series C | $55M | - |
| 15.10.2015 | Series A | $52M | - |
Mentions in press and media 24
| Date | Title | Description |
| 12.03.2025 | Shift Bioscience announces key appointments to advance rejuvenation therapeutics pipeline | Jill Reckless (CEO, RxCelerate) appointed as Translation Advisor Laurence Reid joins as Non-Executive Director, previously Decibel Therapeutics, Warp Drive Bio, Alnylam, and Millennium Pharmaceuticals Cambridge, UK, 12 March 2025: Shift Bio... |
| 04.02.2021 | Decibel and Catalent Sign Development and Manufacturing Agreement for Dual-Vector Gene Therapy for the Treatment of Congenital Hearing Loss | Partnering early with innovative companies allows us to develop and optimize robust, scalable manufacturing processes and the analytical methods to assess them. SOMERSET, N.J. and BOSTON (PRWEB) February 04, 2021 Catalent, the leading globa... |
| 11.11.2020 | Clinical-Stage Biotechnology Company Decibel Therapeutics Raises US$ 82.2M | - |
| 10.11.2020 | Decibel Therapeutics lands $82M+ for hearing loss treatment | Decibel Therapeutics, a developer of treatments for hearing loss and balance disorders, has raised $82.2 million in an oversubscribed Series D. The round was led by OrbiMed, with new investors such as BlackRock Health Sciences, Janus Hender... |
| 09.11.2020 | Decibel Therapeutics Nets $82M Series D Round | BOSTON, MA, Decibel Therapeutics has closed an oversubscribed Series D financing led by OrbiMed, which raised $82.2M. >> Click here for more funding data on Decibel Therapeutics >> To export Decibel Therapeutics funding data... |
| 09.11.2020 | Decibel Therapeutics Raises $82M Series D | BOSTON--(BUSINESS WIRE)--Decibel Therapeutics, a clinical-stage biotechnology company developing novel restorative gene therapeutics to treat hearing loss and balance disorders, today announced the closing of an oversubscribed Series D fina... |
| 09.11.2020 | Decibel scores $82M to push hearing loss gene therapy into the clinic W h i t e p a p e r Vital Precision for Cost Reduction, QA, and Regulatory Compliance | Launched in 2015 to tackle hearing loss broadly, Decibel Therapeutics kicked off 2020 with a new CEO and an R&D makeover. Nine months later, it’s grabbing $82 million to propel its lead programs into and through the clinic, including a ... |
| 09.11.2020 | Decibel Therapeutics : Announces $82M Series D Financing to Advance Gene Therapies to Restore Hearing and Balance | Decibel Therapeutics, a clinical-stage biotechnology company developing novel restorative gene therapeutics to treat hearing loss and balance disorders, today announced the closing of an oversubscribed Series D financing, which raised $82.2... |
| 09.11.2020 | Decibel scores $82M to push hearing loss gene therapy into the clinic | Launched in 2015 to tackle hearing loss broadly, Decibel Therapeutics kicked off 2020 with a new CEO and an R&D makeover. Nine months later, it’s grabbing $82 million to propel its lead programs into and through the clinic, including a ... |
| 11.09.2020 | Decibel Therapeutics : Announces $82M Series D Financing to Advance Gene Therapies to Restore Hearing and Balance | Decibel Therapeutics, a clinical-stage biotechnology company developing novel restorative gene therapeutics to treat hearing loss and balance disorders, today announced the closing of an oversubscribed Series D financing, which raised $82.2... |
Show more